Allopregnanolone potentiates a GABA-withdrawal syndrome in the rat cerebral cortex.
We have studied the neuromodulatory effect of the neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one (allopregnanolone-3 alpha-5 alpha P-) in the GABA-withdrawal syndrome (GWS). This is a model of partial epilepsy consisting of an enduring paraoxysmal activity recorded at the site of GABA infusion that depends, for its induction, on GABA receptor activation. Rats were chronically implanted for frontal and occipital EEG recording with infusion cannulae fixed on the somatomotor cortical region. When the neurosteroid was infused after or concurrently with GABA, a potentiation of the GWS (i.e. shorter latency and prolonged duration) was observed. No modifications in EEG activity were detected when allopregnanolone was administered alone or prior to GABA administration. These results indicate a neuromodulatory effect of allopregnanolone, dependent on the presence of GABA at the receptor site.
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D002540:Cerebral Cortex / Q000187:drug effects*; D004195:Disease Models, Animal; D004357:Drug Synergism; D004569:Electroencephalography; D004828:Epilepsies, Partial / Q000139:chemically induced; D008297:Male; D009474:Neurons / Q000187:drug effects; D011280:Pregnanolone / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013375:Substance Withdrawal Syndrome; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects*
D014151:Anti-Anxiety Agents; D005680:gamma-Aminobutyric Acid; D011280:Pregnanolone